NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting, where it will present its recently cleared OneRF Trigeminal Nerve Ablation System and provide updates on its investigational SEEG-Drug Delivery System. The meeting takes place May 30-June 2 in Cleveland, Ohio.
The OneRF Trigeminal Nerve Ablation System, which received FDA 510(k) clearance under K251243, is designed for creating radiofrequency lesions to treat chronic facial pain or for lesioning nerve tissue in functional neurosurgical procedures. According to the company, the system features a multi-contact RF probe that enables precise mapping and ablation in fewer cycles without repositioning, potentially reducing procedural time and improving patient comfort. NeuroOne recently completed the limited market release of this system.
In addition to the trigeminal nerve ablation system, NeuroOne will share details on its SEEG-Drug Delivery System, currently under development for investigational use in humans and research in laboratory animals. The device is being designed to deliver drugs, record neural activity, and stimulate, while supporting multiple trajectories and enabling repeated dosing through a single implant. This platform could expand the capabilities of stereoelectroencephalography (SEEG) beyond recording and ablation to include targeted drug delivery.
NeuroOne will present a scientific presentation titled "Integrating Drug Delivery Capabilities into a SEEG-Based Recording, Stimulation, and Ablation Platform Technology" during a parallel session on device development on May 31. The company will also display posters on SEEG-guided radiofrequency ablation with real-time temperature control and a cadaveric feasibility study of the new multi-contact RF probe for trigeminal neuralgia.
The company noted that multiple neurosurgeons will present their clinical experiences with both the OneRF Radiofrequency Ablation System (for brain) and the OneRF Trigeminal Nerve Ablation System during the meeting.
This presentation comes at a time when the medical community is increasingly focused on minimally invasive solutions for neurological disorders. NeuroOne's technology platform, which includes four FDA-cleared product families, aims to reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes. The SEEG-Drug Delivery System, if successfully developed and approved, could represent a significant advancement in the treatment of conditions requiring both electrical modulation and pharmacological intervention.
NeuroOne is a medical technology company based in Eden Prairie, Minnesota, dedicated to transforming surgical diagnosis and treatment of neurological disorders. Its products include Evo Cortical Electrodes, Evo sEEG Electrodes, and the OneRF Ablation System for brain, in addition to the newly cleared trigeminal nerve ablation system. The company is also engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. More information can be found at nmtc1.com.
